Virgil Thompson

Virgil Thompson

Virgil Thompson, Director

Mr. Thompson has been a director since August 2014 and is a member of Mallinckrodt’s Human Resources and Compensation Committee.

From July 2009 to July 2015, he served as chief executive officer and director of Spinnaker Biosciences, Inc., and now serves as chairman of the board. Mr. Thompson is also the chairman of the board of Aradigm Corporation and a director of GenZ Corporation.

Mr. Thompson served as a director of Questcor Pharmaceuticals, Inc. from 1996 — and most recently served as chairman of its board — until Questcor was acquired by Mallinckrodt in August 2014. Mr. Thompson served as the president, chief executive officer and as a director of Angstrom Pharmaceuticals, Inc. from 2002 until 2007. From 2000 until 2002, Mr. Thompson was president, chief executive officer and a director of Chimeric Therapies, Inc. From 1999 until 2000, Mr. Thompson was president, chief operating officer and, from 1994, a director of Bio-Technology General Corporation (subsequently Savient Pharmaceuticals, Inc.).

Mr. Thompson holds a bachelor’s degree in pharmacy from the University of Kansas and a J.D. degree from The George Washington University Law School.